Clinical Trial Update: 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption [Phase 2]

View source ↗

Summary

Phase 2 trial updates on the monoclonal antibody 3BNC117 in HIV-1 infection during treatment interruption have completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• 3BNC117

Snippet

Sponsor: Rockefeller University | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2020-07-23